https://www.selleckchem.com/pr....oducts/wortmannin.ht
T-DXd represents successful "antibody engineering". Since the beginning of the year, T-DXd has also been approved in Europe as monotherapy for inoperable or metastatic HER2-positive breast cancer in patients who are pretreated with at least two anti-HER2 directed therapies. This paper presents strategies for improving treatment options in advanced nonoperable and metastatic HER2-positive breast cancer, with the development of T-DXd as an example.The continuous availability of findings from new studies repeatedly results in updated tr
Like
Comment
Share
